Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)

NCT02007239

PHASE2INTERVENTIONAL

Children's Hospital of Philadelphia

0

Started 2013-12 · Completed 2021-05

Status: Withdrawn (as of 12-23-2025)

Conditions

Hemophagocytic Lymphohistiocytosis

Interventions

DRUG: tocilizumab

Linked Papers (from SciSciNet-V2)

Total Papers5

Background

3

Result

0

Derived

0

Unknown

2

View on ClinicalTrials.gov

Total Citations Per Year

Brief Summary

This study seeks to determine the efficacy of tocilizumab (TCZ) in patients with hemophagocytic lymphohistiocytosis (HLH) and high cytokine levels (proteins involved in inflammation) in an attempt to decrease the damage caused by these proteins; and secondarily to assess its safety and impact on disease activity.

Sort by:

Background Papers6

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

3,217 citations

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

3,217 citations

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor

Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers2

Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation

Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome